Cargando…

Effect of Levosimendan on Acute Decompensated Right Heart Failure in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension

AIMS: Acute decompensated right heart failure (RHF) in chronic precapillary pulmonary hypertension is often typified by a swiftly progressive syndrome involving systemic congestion. This results from the impairment of the right ventricular filling and/or a reduction in the flow output of the right v...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Chao, Feng, Wei, Zhao, Qi, Liu, Qi, Luo, Xing, Wang, Gang, Sun, Meng, Yao, Zhibo, Sun, Yufei, Hou, Shenglong, Zhao, Chunyang, Zhang, Ruoxi, Qu, Xiufen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931274/
https://www.ncbi.nlm.nih.gov/pubmed/35308558
http://dx.doi.org/10.3389/fmed.2022.778620
_version_ 1784671222018080768
author Qu, Chao
Feng, Wei
Zhao, Qi
Liu, Qi
Luo, Xing
Wang, Gang
Sun, Meng
Yao, Zhibo
Sun, Yufei
Hou, Shenglong
Zhao, Chunyang
Zhang, Ruoxi
Qu, Xiufen
author_facet Qu, Chao
Feng, Wei
Zhao, Qi
Liu, Qi
Luo, Xing
Wang, Gang
Sun, Meng
Yao, Zhibo
Sun, Yufei
Hou, Shenglong
Zhao, Chunyang
Zhang, Ruoxi
Qu, Xiufen
author_sort Qu, Chao
collection PubMed
description AIMS: Acute decompensated right heart failure (RHF) in chronic precapillary pulmonary hypertension is often typified by a swiftly progressive syndrome involving systemic congestion. This results from the impairment of the right ventricular filling and/or a reduction in the flow output of the right ventricle, which has been linked to a dismal prognosis of short duration. Despite this, there are limited therapeutic data regarding these acute incidents. This study examined the effect of levosimendan on acute decompensated RHF in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH). METHODS: This retrospective study included 87 patients with confirmed CTD-PAH complicated acute decompensated RHF between November 2015 and April 2021. We collected biological, clinical, and demographic data, as well as therapy data, from patients with acute decompensated RHF who required levosimendan treatment in the cardiac care unit (CCU) for CTD-PAH. The patients were divided into two groups according to the levosimendan treatment. Patient information between the two groups was systematically compared in hospital and at follow-up. RESULTS: Oxygen saturation of mixed venose blood (SvO(2)), estimated glomerular filtration rate (eGFR), 24-h urine output, and tricuspid annular plane systolic excursion (TAPSE) were found to be considerably elevated in the levosimendan cohort compared with the control cohort. Patients in the levosimendan cohort exhibited considerably reduced levels of C-reactive protein (CRP), white blood cell (WBC), troponin I, creatinine, NT-proBNP, and RV diameter compared with those in the control cohort. A higher survival rate was observed in the levosimendan cohort. CONCLUSIONS: Levosimendan treatment could effectively improve acute decompensated RHF and systemic hemodynamics in CTD-PAH patients, with positive effects on survival in hospital and can, therefore, be considered as an alternative treatment option for improving clinical short-term outcomes.
format Online
Article
Text
id pubmed-8931274
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89312742022-03-19 Effect of Levosimendan on Acute Decompensated Right Heart Failure in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension Qu, Chao Feng, Wei Zhao, Qi Liu, Qi Luo, Xing Wang, Gang Sun, Meng Yao, Zhibo Sun, Yufei Hou, Shenglong Zhao, Chunyang Zhang, Ruoxi Qu, Xiufen Front Med (Lausanne) Medicine AIMS: Acute decompensated right heart failure (RHF) in chronic precapillary pulmonary hypertension is often typified by a swiftly progressive syndrome involving systemic congestion. This results from the impairment of the right ventricular filling and/or a reduction in the flow output of the right ventricle, which has been linked to a dismal prognosis of short duration. Despite this, there are limited therapeutic data regarding these acute incidents. This study examined the effect of levosimendan on acute decompensated RHF in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH). METHODS: This retrospective study included 87 patients with confirmed CTD-PAH complicated acute decompensated RHF between November 2015 and April 2021. We collected biological, clinical, and demographic data, as well as therapy data, from patients with acute decompensated RHF who required levosimendan treatment in the cardiac care unit (CCU) for CTD-PAH. The patients were divided into two groups according to the levosimendan treatment. Patient information between the two groups was systematically compared in hospital and at follow-up. RESULTS: Oxygen saturation of mixed venose blood (SvO(2)), estimated glomerular filtration rate (eGFR), 24-h urine output, and tricuspid annular plane systolic excursion (TAPSE) were found to be considerably elevated in the levosimendan cohort compared with the control cohort. Patients in the levosimendan cohort exhibited considerably reduced levels of C-reactive protein (CRP), white blood cell (WBC), troponin I, creatinine, NT-proBNP, and RV diameter compared with those in the control cohort. A higher survival rate was observed in the levosimendan cohort. CONCLUSIONS: Levosimendan treatment could effectively improve acute decompensated RHF and systemic hemodynamics in CTD-PAH patients, with positive effects on survival in hospital and can, therefore, be considered as an alternative treatment option for improving clinical short-term outcomes. Frontiers Media S.A. 2022-03-04 /pmc/articles/PMC8931274/ /pubmed/35308558 http://dx.doi.org/10.3389/fmed.2022.778620 Text en Copyright © 2022 Qu, Feng, Zhao, Liu, Luo, Wang, Sun, Yao, Sun, Hou, Zhao, Zhang and Qu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Qu, Chao
Feng, Wei
Zhao, Qi
Liu, Qi
Luo, Xing
Wang, Gang
Sun, Meng
Yao, Zhibo
Sun, Yufei
Hou, Shenglong
Zhao, Chunyang
Zhang, Ruoxi
Qu, Xiufen
Effect of Levosimendan on Acute Decompensated Right Heart Failure in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
title Effect of Levosimendan on Acute Decompensated Right Heart Failure in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
title_full Effect of Levosimendan on Acute Decompensated Right Heart Failure in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
title_fullStr Effect of Levosimendan on Acute Decompensated Right Heart Failure in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
title_full_unstemmed Effect of Levosimendan on Acute Decompensated Right Heart Failure in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
title_short Effect of Levosimendan on Acute Decompensated Right Heart Failure in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
title_sort effect of levosimendan on acute decompensated right heart failure in patients with connective tissue disease-associated pulmonary arterial hypertension
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931274/
https://www.ncbi.nlm.nih.gov/pubmed/35308558
http://dx.doi.org/10.3389/fmed.2022.778620
work_keys_str_mv AT quchao effectoflevosimendanonacutedecompensatedrightheartfailureinpatientswithconnectivetissuediseaseassociatedpulmonaryarterialhypertension
AT fengwei effectoflevosimendanonacutedecompensatedrightheartfailureinpatientswithconnectivetissuediseaseassociatedpulmonaryarterialhypertension
AT zhaoqi effectoflevosimendanonacutedecompensatedrightheartfailureinpatientswithconnectivetissuediseaseassociatedpulmonaryarterialhypertension
AT liuqi effectoflevosimendanonacutedecompensatedrightheartfailureinpatientswithconnectivetissuediseaseassociatedpulmonaryarterialhypertension
AT luoxing effectoflevosimendanonacutedecompensatedrightheartfailureinpatientswithconnectivetissuediseaseassociatedpulmonaryarterialhypertension
AT wanggang effectoflevosimendanonacutedecompensatedrightheartfailureinpatientswithconnectivetissuediseaseassociatedpulmonaryarterialhypertension
AT sunmeng effectoflevosimendanonacutedecompensatedrightheartfailureinpatientswithconnectivetissuediseaseassociatedpulmonaryarterialhypertension
AT yaozhibo effectoflevosimendanonacutedecompensatedrightheartfailureinpatientswithconnectivetissuediseaseassociatedpulmonaryarterialhypertension
AT sunyufei effectoflevosimendanonacutedecompensatedrightheartfailureinpatientswithconnectivetissuediseaseassociatedpulmonaryarterialhypertension
AT houshenglong effectoflevosimendanonacutedecompensatedrightheartfailureinpatientswithconnectivetissuediseaseassociatedpulmonaryarterialhypertension
AT zhaochunyang effectoflevosimendanonacutedecompensatedrightheartfailureinpatientswithconnectivetissuediseaseassociatedpulmonaryarterialhypertension
AT zhangruoxi effectoflevosimendanonacutedecompensatedrightheartfailureinpatientswithconnectivetissuediseaseassociatedpulmonaryarterialhypertension
AT quxiufen effectoflevosimendanonacutedecompensatedrightheartfailureinpatientswithconnectivetissuediseaseassociatedpulmonaryarterialhypertension